Publications by authors named "Elke Prasad"

Article Synopsis
  • Additive manufacturing in pharmaceuticals allows for precise control over the micro-structure and drug release profiles of oral solid doses (OSDs), customizing dosing of active ingredients.
  • The study introduced the MicroFactory, a novel, filament-free 3D printing process that enables the production of an immediate release form of mefenamic acid, overcoming previous limitations due to material brittleness.
  • Characterization techniques confirmed the preserved crystalline properties of mefenamic acid in the printed formulations, resulting in uniform mass and drug content while achieving effective, consistent release profiles.
View Article and Find Full Text PDF

Polymorphism and crystal habit play vital roles in dictating the properties of crystalline materials. Here, the structure and properties of oxcarbazepine (OXCBZ) form III are reported along with the occurrence of twisted crystalline aggregates of this metastable polymorph. OXCBZ III can be produced by crystallization from the vapor phase and by recrystallization from solution.

View Article and Find Full Text PDF

With advancements in the pharmaceutical industry pushing more towards tailored medicines, novel approaches to tablet manufacture are in high demand. One of the main drivers towards micro-scale batch production is the ability to fine-tune drug release. This study demonstrates the use of rapid tooling injection moulding (RTIM) for tablet manufacture.

View Article and Find Full Text PDF

The objective of this study was to develop an immediate release (IR), crystalline solid dispersion (CSD) formulation of Mefenamic acid (MFA) by hot-melt-extrusion (HME) and assess the impact of drug loading on process parameters, product physico-chemical properties and product performance. An HME process to produce a range of MFA-Soluplus®-Sorbitol polymer matrix CSD formulations was developed based on rheological screening assays of physical mixtures (PM). The impact of drug loading on process parameters was compared to the impact of drug loading on the physico-chemical properties of formulations.

View Article and Find Full Text PDF

The objective of this study was to develop an immediate release dose form containing 250 mg Mefenamic acid (MFA) presented as a crystalline solid dispersion in order to achieve improved consistency in drug release through a simplified formulation compared to a commercial product. An MFA-Soluplus®-Sorbitol polymer matrix was developed using an HME process based on rheological screening assays of physical mixtures. The physico-chemical properties of these formulations were assessed by thermal analysis, FTIR, mechanical testing and SEM image analysis, confirming the crystalline character and stable polymorphic form I of the API in the polymer matrix.

View Article and Find Full Text PDF